Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions – A presentation on 4-week weight loss data from CT-388, a once weekly, dual GLP-1/GIP receptor modulator being developed for obese patients with and without type 2 diabetes – – Two presentations on...

Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease – Spin-off of technology platform to newly-formed Kimia Therapeutics intended to maximize the full potential of Carmot’s metabolic portfolio while enabling Kimia to pursue a broad range of...